References
- Urban J L, Schreiber H. Tumor antigens. Annu Rev Immunol 1992; 10: 617–644
- Ellisen L W, Carlesso N, Cheng T, Scadden D T, Haber D A. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001; 20: 1897–1909
- Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121
- Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969–2976
- Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132–2137
- Rezvani K, Yong A S, Savani B N, Mielke S, Keyvanfar K, Gostick E, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007; 110: 1924–1932
- Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004; 101: 13885–13890
- Rezvani K, Yong A S, Mielke S, Savani B N, Musse L, Superata J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242
- Al Qudaihi G, Lehe C, Negash M, Al Alwan M, Ghebeh H, Mohamed S, Saleh A, et al. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic Tlymphocytes generated against a WT1 peptide analog. Leuk Lymphoma 2009; 50: 260–269